{"id":58188,"date":"2023-10-10T13:01:36","date_gmt":"2023-10-10T11:01:36","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/"},"modified":"2023-10-10T13:01:36","modified_gmt":"2023-10-10T11:01:36","slug":"merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/","title":{"rendered":"Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<b>First Phase 3 survival data from KEYNOTE-A39\/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for ESMO Presidential Symposium Session and official Press Briefings<\/b><\/p>\n<p class=\"bwalignc\">\n<b>Key data to be presented for KEYTRUDA<sup>\u00ae <\/sup>(pembrolizumab) in earlier stages of cancer across multiple tumor types, including presentation of overall survival results from KEYNOTE-671, and new and updated data from KEYNOTE-A18, KEYNOTE-522 and KEYNOTE-756<\/b><\/p>\n<p class=\"bwalignc\">\n<b>First Phase 3 data from LITESPARK-005 trial highlight potential of WELIREG<sup>\u00ae<\/sup> (belzutifan) in certain previously treated patients with advanced renal cell carcinoma<\/b><\/p>\n<p>RAHWAY, N.J.&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/search?q=%24MRK&amp;src=ctag\" target=\"_blank\" rel=\"noopener\">$MRK<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/MRK?src=hash\" target=\"_blank\" rel=\"noopener\">#MRK<\/a>&#8211;Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and three pipeline candidates in more than 15 types of cancer will be presented at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, from Oct. 20-24. Presentations will feature new or updated findings from Merck\u2019s broad portfolio of cancer medicines: KEYTRUDA, Merck\u2019s anti-PD-1 therapy; WELIREG, Merck\u2019s oral hypoxia-inducible factor-2 alpha (HIF-2\u03b1) inhibitor; LENVIMA<sup>\u00ae<\/sup> (lenvatinib), in collaboration with Eisai; and LYNPARZA<sup>\u00ae<\/sup> (olaparib), in collaboration with AstraZeneca, and emphasize Merck\u2019s commitment to improving outcomes for patients across multiple stages of cancer.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20231010317131\/en\/1106824\/5\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20231010317131\/en\/1106824\/21\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20231010317131\/en\/1106824\/5\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20231010317131\/en\/1106824\/22\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg\"><\/a><\/p>\n<p>\nAdditionally, new data from Merck\u2019s diverse pipeline will be shared at the congress, including from MK-1084, a KRAS G12C inhibitor being evaluated as monotherapy and in combination with KEYTRUDA; from MK-2870 (also known as SKB264), an anti-TROP2 antibody drug conjugate (ADC) being developed in collaboration with Kelun-Biotech; and from V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT) being developed in collaboration with Moderna, in combination with KEYTRUDA.<\/p>\n<p>\n\u201c<!-- no quote -->At ESMO 2023, we look forward to sharing new research highlighting the breadth of our portfolio and expanding pipeline, as we pursue breakthrough innovations in oncology to address critical gaps in care for patients in need,\u201d said Dr. Marjorie Green, senior vice president and head of late-stage oncology, global clinical development, Merck Research Laboratories. \u201c<!-- no quote -->Our continued efforts to treat cancer earlier and make a meaningful impact are fueled by one goal: To give those who are counting on us more effective ways to treat their cancer.\u201d<\/p>\n<p>\n<b>Key data from Merck\u2019s portfolio to be presented at ESMO Congress 2023:<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFirst presentation of survival data from the Phase 3 KEYNOTE-A39\/EV-302 trial evaluating KEYTRUDA plus enfortumab vedotin as a first-line treatment for patients with locally advanced or metastatic urothelial carcinoma (Presentation #LBA6,) which will be featured in an ESMO Presidential Symposium and as part of the ESMO Press Briefings;<\/li>\n<li>\nPresentation of overall survival (OS) results from the Phase 3 KEYNOTE-671 study evaluating KEYTRUDA in the perioperative setting (neoadjuvant KEYTRUDA plus chemotherapy followed by resection and adjuvant KEYTRUDA as a single agent) for resectable stage II, IIIA or IIIB non-small cell lung cancer (NSCLC) (Presentation #LBA56);<\/li>\n<li>\nFirst presentation of data from the Phase 3 KEYNOTE-A18 trial evaluating KEYTRUDA plus chemoradiotherapy in patients with high-risk, locally advanced cervical cancer (Presentation #LBA38);<\/li>\n<li>\nFirst presentation of data from the Phase 3 KEYNOTE-756 trial evaluating KEYTRUDA plus neoadjuvant chemotherapy and adjuvant endocrine therapy in early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+\/HER2-) breast cancer (Presentation #LBA21);<\/li>\n<li>\nFirst presentation of data from the Phase 3 LITESPARK-005 trial evaluating WELIREG for the treatment of patients with advanced renal cell carcinoma (aRCC) previously treated with immune checkpoint and anti-angiogenic therapies (Presentation #LBA88);<\/li>\n<li>\nFirst time presentation of progression-free survival (PFS) and OS data from the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA plus trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma (Presentation #1511O);<\/li>\n<li>\nUpdated 5-year event-free survival data from the Phase 3 KEYNOTE-522 trial evaluating KEYTRUDA in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment for patients with high-risk early-stage triple-negative breast cancer (TNBC) (Presentation #LBA18).<\/li>\n<\/ul>\n<p>\n<b>Key data from Merck\u2019s pipeline to be presented at ESMO Congress 2023:<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFirst-time safety and preliminary efficacy data for MK-1084, a KRAS G12C inhibitor, as a monotherapy in solid tumors and in combination with KEYTRUDA in NSCLC (Presentation #663P);<\/li>\n<li>\nFirst presentation of data from a Phase 2 cohort of the Phase 1\/2 trial evaluating MK-2870 (also known as SKB264) in previously treated metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (Presentation #380MO);<\/li>\n<li>\nAdditional data from the Phase 2b KEYNOTE-942\/mRNA-4157-P201 trial evaluating V940 (mRNA-4157) in combination with KEYTRUDA as adjuvant treatment for high-risk melanoma (Presentation # LBA49).<\/li>\n<\/ul>\n<p>\n<b>Merck investor event<\/b><\/p>\n<p>\nMerck will host an Oncology Investor Event to coincide with the ESMO Congress 2023 on Sunday, October 22, 2023, 7:00 p.m. CEST\/1:00 p.m. ET, at which senior management will highlight key data presentations. The event will take place virtually and will be accessible via webcast. Investors, analysts, members of the media and the general public are invited to listen to a webcast of the presentation at: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fonlinexperiences.com%2FLaunch%2FQReg%2FShowUUID%3D9CC730AB-52D5-4ABB-8D7E-4A01DC92F832%26LangLocaleID%3D1033&amp;esheet=53584628&amp;newsitemid=20231010317131&amp;lan=en-US&amp;anchor=https%3A%2F%2Fonlinexperiences.com%2FLaunch%2FQReg%2FShowUUID%3D9CC730AB-52D5-4ABB-8D7E-4A01DC92F832%26amp%3BLangLocaleID%3D1033&amp;index=1&amp;md5=1808a710d82d0e0d00fc5eee63ccc955\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/onlinexperiences.com\/Launch\/QReg\/ShowUUID=9CC730AB-52D5-4ABB-8D7E-4A01DC92F832&amp;LangLocaleID=1033<\/a><\/p>\n<p>\n<b>Details on abstracts listed above and additional key abstracts related to Merck\u2019s portfolio and pipeline at ESMO Congress 2023:<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Breast cancer<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)\/ HER2-negative metastatic breast cancer (mBC): Results from a phase I\/II, single-arm, basket trial. Y. Yin.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #380MO, Mini oral session &#8211; Breast cancer, metastatic<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase 3 KEYNOTE-522 study. P. Schmid.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation # LBA18, Proffered Paper session &#8211; Breast cancer, early stage<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nKEYNOTE-756: Phase 3 study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+\/HER2\u2013 breast cancer. F. Cardoso. (Led by Kelun-Biotech)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation # LBA21, Proffered Paper session &#8211; Breast cancer, early stage<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Gastrointestinal cancers<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)\/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase 3 KEYNOTE-177 study. K. Shiu.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #LBA32, Mini oral session &#8211; Gastrointestinal tumours, lower digestive<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nImpact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER. J. Strickler. (Led by Seagen)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #551O, Proffered Paper session 1 &#8211; Gastrointestinal tumours, lower digestive<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: Survival results from the phase 3, randomized, double-blind, placebo-controlled KEYNOTE-811 study. Y. Janjigian.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #1511O, Proffered Paper session 1 &#8211; Gastrointestinal tumours, upper digestive<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHealth-related quality of life (HRQoL) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma. M. Lowery.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #1516P, Poster<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Genitourinary cancers<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEV-302\/KEYNOTE-A39: Open-label, randomized phase 3 study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC). T. Powles.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #LBA6, Presidential 2<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPhase 2 LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC). T. Choueiri.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #LBA87, Proffered Paper session 2 &#8211; Genitourinary tumours, non-prostate<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBelzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase 3 LITESPARK-005 study. L. Albiges.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #LBA88, Proffered Paper session 2 &#8211; Genitourinary tumours, non-prostate<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSafety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase 2 LITESPARK-013 study. N. Agarwal.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #1881O, Proffered Paper session 2 &#8211; Genitourinary tumours, non-prostate<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Gynecologic cancers<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11\/GOG-3047\/KEYNOTE-A18 study. D. Lorusso.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #LBA38, Proffered Paper session 1 &#8211; Gynaecological cancers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUpdated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin\/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial. R. Eskander.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #LBA43, Mini oral session &#8211; Gynaecological cancers<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Lung cancer<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOverall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). J. Spicer.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #LBA56, Proffered Paper session &#8211; Non-metastatic NSCLC and other thoracic malignancies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSafety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC. C. Rojas.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #663P, Poster<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Melanoma<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIB-IV melanoma from SWOG S1801. S. Patel.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation #LBA48, Proffered Paper session &#8211; Melanoma and other skin tumours<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth75\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nmRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response. J. Weber.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation # LBA49, Proffered Paper session &#8211; Melanoma and other skin tumours<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>About Merck\u2019s early-stage cancer clinical program<\/b><\/p>\n<p>\nFinding cancer at an earlier stage may give patients a greater chance of long-term survival. Many cancers are considered most treatable and potentially curable in their earliest stage of disease. Building on the strong understanding of the role of KEYTRUDA in later-stage cancers, Merck is studying KEYTRUDA in earlier disease states, with approximately 20 ongoing registrational studies across multiple types of cancer.<\/p>\n<p>\n<strong>About KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab) injection, 100 mg<\/strong><\/p>\n<p>\nKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.<\/p>\n<p>\nMerck has the industry\u2019s largest immuno-oncology clinical research program. There are currently more than 1,600 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient&#8217;s likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.<\/p>\n<p>\n<b>Selected KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab) Indications in the U.S.<\/b><\/p>\n<p>\n<i>Melanoma<\/i><\/p>\n<p>\nKEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.<\/p>\n<p>\nKEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB, IIC, or III melanoma following complete resection.<\/p>\n<p>\n<i>Non-Small Cell Lung Cancer<\/i><\/p>\n<p>\nKEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.<\/p>\n<p>\nKEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.<\/p>\n<p>\nKEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) \u22651%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nstage III where patients are not candidates for surgical resection or definitive chemoradiation, or<\/li>\n<li>\nmetastatic.<\/li>\n<\/ul>\n<p>\nKEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.<\/p>\n<p>\nKEYTRUDA, as a single agent, is indicated for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage IB (T2a \u22654 cm), II, or IIIA NSCLC.<\/p>\n<p>\n<i>Urothelial Carcinoma<\/i><\/p>\n<p>\nKEYTRUDA, in combination with enfortumab vedotin, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy.<\/p>\n<p>\nThis indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.<\/p>\n<p>\nKEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC):<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nwho are not eligible for any platinum-containing chemotherapy, or<\/li>\n<li>\nwho have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.<\/li>\n<\/ul>\n<p>\nKEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.<\/p>\n<p>\n<i>Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer<\/i><\/p>\n<p>\nKEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test.<\/p>\n<p>\n<i>Gastric Cancer<\/i><\/p>\n<p>\nKEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.<\/p>\n<p>\nThis indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.<\/p>\n<p>\n<i>Esophageal Cancer<\/i><\/p>\n<p>\nKEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nin combination with platinum- and fluoropyrimidine-based chemotherapy, or<\/li>\n<li>\nas a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS \u226510) as determined by an FDA-approved test.<\/li>\n<\/ul>\n<p>\nKEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum and fluoropyrimidine-based chemotherapy.<\/p>\n<p>\n<i>Cervical Cancer<\/i><\/p>\n<p>\nKEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS \u22651) as determined by an FDA-approved test.<\/p>\n<p>\nKEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS \u22651) as determined by an FDA-approved test.<\/p>\n<p>\n<i>Endometrial Carcinoma<\/i><\/p>\n<p>\nKEYTRUDA, in combination with LENVIMA, is indicated for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) as determined by an FDA-approved test or not MSI-H, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.<\/p>\n<p>\nKEYTRUDA, as a single agent, is indicated for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.<\/p>\n<p>\n<i>Triple-Negative Breast Cancer<\/i><\/p>\n<p>\nKEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.<\/p>\n<p>\nKEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS \u226510) as determined by an FDA-approved test.<\/p>\n<p>\n<i>See additional selected KEYTRUDA indications in the U.S. after the Selected Important Safety Information.<\/i><\/p>\n<p>\n<b>Selected Important Safety Information for KEYTRUDA<\/b><\/p>\n<p>\n<b>Severe and Fatal Immune-Mediated Adverse Reactions<\/b><\/p>\n<p>\nKEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the PD-1 or the PD-L1, blocking the PD-1\/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can affect more than one body system simultaneously, and can occur at any time after starting treatment or after discontinuation of treatment. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.<\/p>\n<p>\nMonitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Early identification and management are essential to ensure safe use of anti\u2013PD-1\/PD-L1 treatments. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. For patients with TNBC treated with KEYTRUDA in the neoadjuvant setting, monitor blood cortisol at baseline, prior to surgery, and as clinically indicated. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.<\/p>\n<p>\nWithhold or permanently discontinue KEYTRUDA depending on severity of the immune-mediated adverse reaction. In general, if KEYTRUDA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg\/kg\/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroid therapy.<\/p>\n<p>\n<span class=\"bwuline\">Immune-Mediated Pneumonitis<\/span><\/p>\n<p>\nKEYTRUDA can cause immune-mediated pneumonitis. The incidence is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 3.4% (94\/2799) of patients receiving KEYTRUDA, including fatal (0.1%), Grade 4 (0.3%), Grade 3 (0.9%), and Grade 2 (1.3%) reactions. Systemic corticosteroids were required in 67% (63\/94) of patients. Pneumonitis led to permanent discontinuation of KEYTRUDA in 1.3% (36) and withholding in 0.9% (26) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Pneumonitis resolved in 59% of the 94 patients.<\/p>\n<p>\nPneumonitis occurred in 8% (31\/389) of adult patients with cHL receiving KEYTRUDA as a single agent, including Grades 3-4 in 2.3% of patients. Patients received high-dose corticosteroids for a median duration of 10 days (range: 2 days to 53 months). Pneumonitis rates were similar in patients with and without prior thoracic radiation. Pneumonitis led to discontinuation of KEYTRUDA in 5.4% (21) of patients. Of the patients who developed pneumonitis, 42% interrupted KEYTRUDA, 68% discontinued KEYTRUDA, and 77% had resolution.<\/p>\n<p>\nPneumonitis occurred in 7% (41\/580) of adult patients with resected NSCLC who received KEYTRUDA as a single agent for adjuvant treatment of NSCLC, including fatal (0.2%), Grade 4 (0.3%), and Grade 3 (1%) adverse reactions. Patients received high-dose corticosteroids for a median duration of 10 days (range: 1 day to 2.3 months). Pneumonitis led to discontinuation of KEYTRUDA in 26 (4.5%) of patients. Of the patients who developed pneumonitis, 54% interrupted KEYTRUDA, 63% discontinued KEYTRUDA, and 71% had resolution.<\/p>\n<p>\n<span class=\"bwuline\">Immune-Mediated Colitis<\/span><\/p>\n<p>\nKEYTRUDA can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus infection\/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-mediated colitis occurred in 1.7% (48\/2799) of patients receiving KEYTRUDA, including Grade 4 (&lt;0.1%), Grade 3 (1.1%), and Grade 2 (0.4%) reactions. Systemic corticosteroids were required in 69% (33\/48); additional immunosuppressant therapy was required in 4.2% of patients. Colitis led to permanent discontinuation of KEYTRUDA in 0.5% (15) and withholding in 0.5% (13) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Colitis resolved in 85% of the 48 patients.<\/p>\n<p>\n<span class=\"bwuline\">Hepatotoxicity and Immune-Mediated Hepatitis<\/span><\/p>\n<p>\n<i>KEYTRUDA as a Single Agent<\/i><\/p>\n<p>\nKEYTRUDA can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 0.7% (19\/2799) of patients receiving KEYTRUDA, including Grade 4 (&lt;0.1%), Grade 3 (0.4%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 68% (13\/19) of patients; additional immunosuppressant therapy was required in 11% of patients.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nMedia Contacts:<\/p>\n<p>Julie Cunningham<br \/>\n<br \/>(617) 519-6264<\/p>\n<p>Kristen Drake<br \/>\n<br \/>(908) 740-1679<\/p>\n<p>Investor Contacts:<\/p>\n<p>Peter Dannenbaum<br \/>\n<br \/>(732) 594-1579<\/p>\n<p>Damini Chokshi<br \/>\n<br \/>(732) 594-1579<\/p>\n<p> <a href=\"http:\/\/www.businesswire.com\/news\/home\/20231010317131\/en\/Merck-Highlights-Innovative-Oncology-Portfolio-and-Pipeline-at-ESMO-Congress-2023-Underscoring-Commitment-to-Advancing-Cancer-Research-and-Improving-Patient-Outcomes-Across-Multiple-Stages-of-Disease\/?feedref=Zd8jjkgYuzBwDixoAdXmJgT1albrG1Eq4mAeVP392103_ypKzv-7ah0oHKWbnuHnevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxZM7XiMhduiSeKMTNDLRqI_doMC3CVAuyHo5cJ7XfDuvA==\"> Read full story here <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>First Phase 3 survival data from KEYNOTE-A39\/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for ESMO Presidential Symposium Session and official Press Briefings Key data to be presented for KEYTRUDA\u00ae (pembrolizumab) in earlier stages of cancer across multiple tumor types, including presentation of overall &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58188","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"First Phase 3 survival data from KEYNOTE-A39\/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for ESMO Presidential Symposium Session and official Press Briefings Key data to be presented for KEYTRUDA\u00ae (pembrolizumab) in earlier stages of cancer across multiple tumor types, including presentation of overall ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-10T11:01:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20231010317131\/en\/1106824\/21\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease\",\"datePublished\":\"2023-10-10T11:01:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\\\/\"},\"wordCount\":3150,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231010317131\\\/en\\\/1106824\\\/21\\\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\\\/\",\"name\":\"Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231010317131\\\/en\\\/1106824\\\/21\\\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg\",\"datePublished\":\"2023-10-10T11:01:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231010317131\\\/en\\\/1106824\\\/21\\\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231010317131\\\/en\\\/1106824\\\/21\\\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/","og_locale":"en_US","og_type":"article","og_title":"Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease - Pharma Trend","og_description":"First Phase 3 survival data from KEYNOTE-A39\/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for ESMO Presidential Symposium Session and official Press Briefings Key data to be presented for KEYTRUDA\u00ae (pembrolizumab) in earlier stages of cancer across multiple tumor types, including presentation of overall ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/","og_site_name":"Pharma Trend","article_published_time":"2023-10-10T11:01:36+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20231010317131\/en\/1106824\/21\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease","datePublished":"2023-10-10T11:01:36+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/"},"wordCount":3150,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231010317131\/en\/1106824\/21\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/","url":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/","name":"Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231010317131\/en\/1106824\/21\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg","datePublished":"2023-10-10T11:01:36+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20231010317131\/en\/1106824\/21\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20231010317131\/en\/1106824\/21\/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58188"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58188\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}